Argos, Dicerna set IPO terms
Immunotherapy company Argos Therapeutics Inc. (Durham, N.C.) and RNAi company Dicerna Pharmaceuticals Inc. (Watertown, Mass.) set IPO terms on Tuesday. Both companies are seeking to list on NASDAQ. Argos plans to sell 4.3 million shares at $13-$15. At the $14 midpoint, the company would raise $59.5 million and be valued at $247.4 million. Piper Jaffray; Stifel; JMP Securities; and Needham are underwriters. Argos -- which withdrew previous IPO plans in March 2012 -- filed to raise up to $60 million in the offering last month. The company's AGS-003 is in the Phase III ADAPT trial to treat metastatic renal cell carcinoma (RCC), with overall survival (OS) data expected in 1H16. AGS-003 is a second-generation RNA-loaded autologous dendritic cell immunotherapy. ...